ANGO - AngioDynamics, Inc.
21.77 0.00 (0.00%)
After hours: 4:00PM EDT
| Previous Close | 21.68 |
| Open | 21.65 |
| Bid | 21.75 x 1400 |
| Ask | 21.76 x 900 |
| Day's Range | 21.49 - 21.88 |
| 52 Week Range | 18.11 - 25.48 |
| Volume | 152,868 |
| Avg. Volume | 213,162 |
| Market Cap | 810.19M |
| Beta (3Y Monthly) | 0.73 |
| PE Ratio (TTM) | 13.52 |
| EPS (TTM) | 1.61 |
| Earnings Date | Sep 25, 2019 - Sep 30, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 23.67 |
- Thomson Reuters StreetEvents•3 days ago
Edited Transcript of ANGO earnings conference call or presentation 10-Jul-19 12:00pm GMT
Q4 2019 AngioDynamics Inc Earnings Call
- Zacks•4 days ago
AngioDynamics (ANGO) Q4 Earnings Miss, Revenues Top Estimates
AngioDyamics (ANGO) gains from solid segmental contributions in fourth-quarter fiscal 2019.
Motley Fool•4 days agoAngioDynamics (ANGO) Q4 2019 Earnings Call Transcript
ANGO earnings call for the period ending June 30, 2019.
- American City Business Journals•5 days ago
AngioDynamics completes $100 million turnaround
Sales increased by $15 million last year to $359.5 million, with about half of that growth coming from international customers.
- Zacks•5 days ago
AngioDynamics (ANGO) Lags Q4 Earnings Estimates
AngioDynamics (ANGO) delivered earnings and revenue surprises of -3.85% and 3.72%, respectively, for the quarter ended May 2019. Do the numbers hold clues to what lies ahead for the stock?
- Simply Wall St.•5 days ago
Is AngioDynamics, Inc.'s (NASDAQ:ANGO) CEO Paid At A Competitive Rate?
Jim Clemmer has been the CEO of AngioDynamics, Inc. (NASDAQ:ANGO) since 2016. First, this article will compare CEO...
- Business Wire•5 days ago
AngioDynamics Reports Fiscal 2019 Fourth Quarter and Full-Year Financial Results
Fiscal 2019 Fourth Quarter Highlights
- ACCESSWIRE•5 days ago
AngioDynamics, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / July 10, 2019 / AngioDynamics, Inc. (NASDAQ: ANGO ) will be discussing their earnings results in their 2019 Fourth Quarter Earnings to be held on July 10, 2019 at 8:00 AM Eastern ...
- Benzinga•6 days ago
Q4 Earnings Outlook For AngioDynamics
AngioDynamics (NASDAQ: ANGO ) unveils its next round of earnings this Wednesday, July 10. Get prepared with Benzinga's ultimate preview for AngioDynamics's Q4 earnings. Earnings and Revenue Wall Street ...
- American City Business Journals•18 days ago
AngioDynamics' bold move: get smaller (for now)
CEO Jim Clemmer was hired in 2016 to turn around AngioDynamics. The plan: Sell off some legacy products and invest in next-generation oncology technology to eventually make the company even bigger.
- Insider Monkey•19 days ago
Is AngioDynamics, Inc. (ANGO) A Good Stock To Buy?
Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns. Hedge funds and institutional investors spend millions of dollars on analysts with MBAs and PhDs, who are industry experts and well connected to other industry and media insiders on top of that. Individual investors can piggyback […]
- Business Wire•25 days ago
AngioDynamics to Report Fiscal 2019 Fourth Quarter and Full-Year Financial Results on July 10, 2019
AngioDynamics, Inc. , a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it will report financial results for the fourth quarter and fiscal year 2019 before the market open on Wednesday, July 10, 2019.
- American City Business Journals•last month
AngioDynamics moving 125 employees into downtown Glens Falls
AngioDynamics will lease the 9th floor of the 10-story Monument Square building in a plan that will bring 125 employees into downtown Glens Falls. The medical device maker is taking approximately 15,000 square feet of office space to accommodate personnel, most of whom previously worked at 10 Glens Falls Technical Park, the former Navilyst building that was sold to Medline Industries last week for $5.75 million. The move is part of AngioDynamics' strategy to improve communication, restructure its manufacturing operations and build a stronger corporate culture, said Dave Helsel, senior vice president of global operations, research and development.
- Zacks•last month
AngioDynamics Divests NAMIC Portfolio to Medline Industries
The NAMIC fluid management portfolio sale clears all of AngioDynamics' (ANGO) outstanding debt.
- Business Wire•last month
AngioDynamics to Present at the Raymond James Life Sciences and MedTech Conference
AngioDynamics, Inc. , a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer, President and Chief Executive Officer, will present at the Raymond James Life Sciences and MedTech Conference at 1:50 p.m.
- Business Wire•last month
AngioDynamics Completes Sale of NAMIC® Fluid Management Portfolio to Medline Industries, Inc.
AngioDynamics, Inc. (ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it closed the previously announced sale of its NAMIC® fluid management portfolio to Medline Industries, Inc. on May 31, 2019 for $167.5 million. AngioDynamics has used a portion of the approximately $160.0 million in net proceeds to pay down all of its outstanding debt. “We are very pleased to have completed the divestiture of the NAMIC fluid management business, which is a critical step in our ongoing portfolio optimization efforts,” said Jim Clemmer, President and Chief Executive Officer of AngioDynamics.
- Business Wire•2 months ago
AngioDynamics to Ring NASDAQ Closing Bell to Celebrate the 15th Anniversary of its Listing on the Exchange
AngioDynamics, Inc. (ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that representatives of the Company will ring the NASDAQ Stock Market closing bell on Tuesday, May 28, 2019 at 4:00 p.m. ET to commemorate the 15-year anniversary of the Company’s listing on the exchange. “NASDAQ has provided AngioDynamics with a robust platform to access the public equity markets and connect with potential shareholders and investors,” said Jim Clemmer, President and Chief Executive Officer of AngioDynamics.
- Zacks•2 months ago
AngioDynamics IDE Application for NanoKnife Gets FDA Nod
AngioDynamics' (ANGO) pilot study is intended to support the approval of a future PMA in the United States.
- Business Wire•2 months ago
AngioDynamics Receives FDA Approval to Initiate Pilot Study for the Use of NanoKnife® to Treat Prostate Cancer
AngioDynamics, Inc. (ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that the United States Food and Drug Administration (FDA) approved the Company’s investigational device exemption (IDE) application for its NanoKnife® Irreversible Electroporation pilot study for the ablation of prostate cancer tissue in low-risk patients. The prospective, non-randomized pilot study includes six subjects at up to three clinical sites.
- Business Wire•2 months ago
AngioDynamics Announces First Patient Enrolled in NanoKnife® DIRECT Clinical Study for the Treatment of Stage III Pancreatic Cancer
The DIRECT Study supports a proposed expanded indication for the NanoKnife System in the treatment of Stage III pancreatic cancer. The first patient enrollment closely follows the United States Food and Drug Administration’s (FDA) April 1, 2019 approval of AngioDynamics’ investigational device exemption (IDE) application.
- Insider Monkey•2 months ago
Here’s What Hedge Funds Think About AngioDynamics, Inc. (ANGO)
World-class money managers like Ken Griffin and Barry Rosenstein only invest their wealthy clients' money after undertaking a rigorous examination of any potential stock. They are particularly successful in this regard when it comes to small-cap stocks, which their peerless research gives them a big information advantage on when it comes to judging their worth. […]
- Zacks•2 months ago
Why Is AngioDynamics (ANGO) Down 12.1% Since Last Earnings Report?
AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Benzinga•3 months ago
The Daily Biotech Pulse: Hookipa To Debut, Mustang Bio Skyrockets, AngioDynamics Sheds Portfolio
Here's a roundup of top developments in the biotech space over the last 24 hours: No biotech stocks hit 52-week highs on Thursday. Down In The Dumps (Biotech stocks hitting 52-week lows on April 17) ABIOMED, ...
- American City Business Journals•3 months ago
AngioDynamics will sell Namic business for $167.5 million
The sale is expected to close by the end of May. Once that occurs, 330 to 350 AngioDynamics employees are expected to join Medline Industries Inc., a privately-held company headquartered near Chicago.
- Business Wire•3 months ago
AngioDynamics Announces Agreement to Sell NAMIC® Fluid Management Business to Medline Industries, Inc. for $167.5 Million
AngioDynamics, Inc. (ANGO), a leading provider of innovative, minimally invasive medical devices for oncology, vascular access, and peripheral vascular disease, today announced that it has entered into a definitive agreement to sell its NAMIC® fluid management portfolio to Medline Industries, Inc. for $167.5 million, subject to customary closing conditions including antitrust review under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. The transaction consists of AngioDynamics’ NAMIC brand and its extensive offering of manifolds, contrast management systems, closed fluid systems, guidewires, disposable transducers, and interventional accessories.
